Anti-EGFR monoclonal antibodies such as cetuximab and panitumumab have become important treatment options for patients with metastatic colorectal cancer (mCRC). However, the presence of specific molecular alterations can significantly influence treatment response. Accurate biomarker testing before initiating therapy is therefore essential to optimize patient selection and avoid ineffective treatment. Here is a quick question on biomarker-guided treatment selection in metastatic colorectal cancer! (Scroll down to answer the question) ##Reference## Karapetis CS, Khambata-Ford S, Jonker DJ, et al.
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1757-65. doi:10.1056/NEJMoa0804385.## ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no explicit…
